Publicaciones en las que colabora con MOISÉS GARCÍA ARENCIBIA (20)

2021

  1. Analogues of cannabinoids as multitarget drugs in the treatment of Alzheimer's disease

    European Journal of Pharmacology, Vol. 895

2018

  1. Benefits of VCE-003.2, a cannabigerol quinone derivative, against inflammation-driven neuronal deterioration in experimental Parkinson's disease: Possible involvement of different binding sites at the PPARγ receptor

    Journal of Neuroinflammation, Vol. 15, Núm. 1

2017

  1. Corrigendum to “Biological characterization of PM226, a chromenoisoxazole, as a selective CB2 receptor agonist with neuroprotective profile” [Pharmacol. Res. (2016) 110(2016) (205–215)] (S1043661816302080) (10.1016/j.phrs.2016.03.021)

    Pharmacological Research

2016

  1. Biological characterization of PM226, a chromenoisoxazole, as a selective CB2 receptor agonist with neuroprotective profile

    Pharmacological Research, Vol. 110, pp. 205-215

  2. Tricyclic pyrazoles. Part 8. Synthesis, biological evaluation and modelling of tricyclic pyrazole carboxamides as potential CB2receptor ligands with antagonist/inverse agonist properties

    European Journal of Medicinal Chemistry, Vol. 112, pp. 66-80

2015

  1. Synthesis, pharmacological evaluation and docking studies of pyrrole structure-based CB2 receptor antagonists

    European Journal of Medicinal Chemistry, Vol. 101, pp. 651-667

2014

  1. Cannabinoid agonists showing BuChE inhibition as potential therapeutic agents for Alzheimer's disease

    European Journal of Medicinal Chemistry, Vol. 73, pp. 56-72

2013

  1. Neuroprotective properties of standardized extracts of hypericum perforatum on rotenone model of parkinson's disease

    CNS and Neurological Disorders - Drug Targets, Vol. 12, Núm. 5, pp. 665-679

2011

  1. Symptom-relieving and neuroprotective effects of the phytocannabinoid Δ 9-THCV in animal models of Parkinson's disease

    British Journal of Pharmacology, Vol. 163, Núm. 7, pp. 1495-1506

2010

  1. A53T-alpha-synuclein overexpression impairs dopamine signaling and striatal synaptic plasticity in old mice

    PLoS ONE, Vol. 5, Núm. 7, pp. 1-15

2009

  1. Cannabinoid CB1 receptors are early DownRegulated followed by a further UpRegulation in the basal Ganglia of mice with deletion of specific park genes

    Journal of Neural Transmission, Supplementa, pp. 269-275

  2. Cannabinoids and Parkinson's Disease

    CNS and Neurological Disorders - Drug Targets, Vol. 8, Núm. 6, pp. 432-439

  3. Parkinson phenotype in aged PINK1-deficient mice is accompanied by progressive mitochondrial dysfunction in absence of neurodegeneration

    PLoS ONE, Vol. 4, Núm. 6

  4. Relación del sistema cannabinoide con la fisiopatología y el tratamiento de la esquizofrenia

    Actualización sobre el potencial terapéutico de los cannabinoides (Sociedad Española de Investigación en Cannabinoides (SEIC)), pp. 239-256

2008

  1. Enhanced striatal glutamate release after the administration of rimonabant to 6-hydroxydopamine-lesioned rats

    Neuroscience Letters, Vol. 438, Núm. 1, pp. 10-13

  2. Potencial terapéutico del sistema cannabinoide en la enfermedad de Parkinson

    Potencial terapéutico del sistema cannabinoide en la enfermedad de Parkinson

  3. Role of CB2 receptors in neuroprotective effects of cannabinoids

    Molecular and Cellular Endocrinology, Vol. 286, Núm. 1-2 SUPPL. 1

2007

  1. Cannabinoids and neuroprotection in Basal ganglia disorders

    Molecular Neurobiology, Vol. 36, Núm. 1, pp. 82-91

  2. Evaluation of the neuroprotective effect of cannabinoids in a rat model of Parkinson's disease: Importance of antioxidant and cannabinoid receptor-independent properties

    Brain Research, Vol. 1134, Núm. 1, pp. 162-170

2006

  1. Effects of rimonabant, a selective cannabinoid CB1 receptor antagonist, in a rat model of Parkinson's disease

    Brain Research, Vol. 1073-1074, Núm. 1, pp. 209-219